Altimmune reported a net loss of $27.4 million for the fourth quarter of 2025, while significantly strengthening its balance sheet to $274 million in cash and short-term investments. The company is transitioning into a late-stage clinical phase with plans to initiate a Phase 3 MASH trial in 2026 following positive FDA alignment and Breakthrough Therapy Designation.

Altimmune announced its Q2 2025 financial results, reporting a net loss of $22.1 million and a net loss per share of $0.27. The company's cash, cash equivalents, and short-term investments increased to $183.1 million. Key highlights include positive 24-week data from the IMPACT Phase 2b trial for pemvidutide in MASH, with significant MASH resolution and weight loss, and the initiation of two new Phase 2 trials for pemvidutide in Alcohol Use Disorder and Alcohol-Associated Liver Disease.

Altimmune maintained a focused R&D strategy in Q1 2025, reducing expenses and strengthening its balance sheet. The company is poised for significant updates in Q2 with the anticipated Phase 2b MASH data readout and new clinical trials in AUD and ALD set to launch.

Altimmune reported a net loss of $23.2 million for the fourth quarter of 2024, with cash, cash equivalents, and short-term investments totaling $131.9 million as of December 31, 2024. The company is advancing pemvidutide in multiple indications and expects to report top-line data from the Phase 2b IMPACT trial in Q2 2025.

Altimmune reported a net loss of $22.8 million, or $0.32 net loss per share, for the third quarter ended September 30, 2024. The company's cash, cash equivalents and short-term investments totaled $139.4 million as of September 30, 2024. Enrollment was completed in the Phase 2b IMPACT trial of pemvidutide in MASH, with top-line efficacy data expected in Q2 2025.

Altimmune reported recent presentations at major medical meetings provide further support for the differentiated profile of pemvidutide in obesity and metabolic dysfunction-associated steatohepatitis (MASH). The company's cash, cash equivalents and short-term investments were $164.9 million on June 30, 2024.

Altimmune reported cash, cash equivalents and short-term investments of $182.1 million. The company's net loss was $24.4 million, or $0.34 net loss per share.

Altimmune reported positive lean mass preservation data for pemvidutide and announced financial results for the fourth quarter and full year 2023. The company's cash, cash equivalents, and short-term investments totaled $198.0 million as of December 31, 2023.

Altimmune reported a net loss of $20.7 million, or $0.39 per share, for the three months ended September 30, 2023. The company's cash, cash equivalents, and short-term investments totaled $140.8 million as of September 30, 2023. Top-line data from the MOMENTUM Phase 2 obesity trial is expected in Q4 2023, and top-line results from the Phase 2 trial of HepTcell in chronic hepatitis B are expected in Q1 2024.

Altimmune reported a net loss of $16.1 million, or $0.32 per share, for the second quarter of 2023. The company's research and development expenses were $13.3 million, and general and administrative expenses were $4.8 million. As of June 30, 2023, Altimmune had cash, cash equivalents, and short-term investments totaling $160.0 million. They also commenced enrollment in the IMPACT Phase 2b trial of pemvidutide in NASH, and top-line results from the MOMENTUM Phase 2 obesity trial are expected in Q4 2023.

Altimmune reported a net loss of $20.1 million, or $0.40 net loss per share, and its cash, cash equivalents and short-term investments totaled $165.8 million as of March 31, 2023. The company is on course for mid-year initiation of IMPACT, its Phase 2b biopsy trial of pemvidutide in subjects with NASH.

Altimmune reported a net loss of $21.7 million for the three months ended December 31, 2022. The company's cash, cash equivalents, and short-term investments totaled $184.9 million as of December 31, 2022.

Altimmune reported minimal revenue and a net loss of $23.5 million for the third quarter of 2022. The company is focused on advancing pemvidutide for obesity and NASH, with data readouts expected in the near term.

Altimmune reported minimal revenue and a net loss for the three months ended June 30, 2022. The company is focused on advancing the development of pemvidutide and expects to announce top line data from clinical trials in the coming months.

Altimmune's Q1 2022 revenue was minimal, research and development expenses increased to $15.1 million, and net loss was $19.4 million, or $0.44 per share. The company's cash, cash equivalents, and restricted cash totaled $180.0 million as of March 31, 2022.

Altimmune reported a revenue of $3.3 million for the three months ended December 31, 2021, compared to $2.3 million in the same period in 2020. The net loss for the three months ended December 31, 2021 was $23.9 million, or $0.57 net loss per share, compared to $10.6 million in the same period in 2020, or $0.29 net loss per share. The company had cash, cash equivalents, short-term investments and restricted cash totaling $190.3 million at December 31, 2021.

Altimmune reported a net loss of $33.5 million for the third quarter of 2021, compared to a net loss of $17.8 million for the same period in 2020. The company's cash, cash equivalents, and short-term investments totaled $199.9 million as of September 30, 2021. Pemvidutide's Phase 1 clinical trial showed positive results, including a reduction in liver fat to undetectable levels in subjects with hepatic steatosis.

Altimmune reported a revenue of $0.1 million and a net loss of $24.8 million, or $0.60 net loss per share for the three months ended June 30, 2021. The company's cash, cash equivalents, short-term investments and restricted cash totaled $217.9 million at June 30, 2021.

Altimmune reported a net loss of $14.9 million, or $0.38 net loss per share, for the three months ended March 31, 2021. The company's cash, cash equivalents and short-term investments totaled $226.5 million at March 31, 2021.

Altimmune reported a net loss of $49.0 million for the year ended December 31, 2020. The company's cash, cash equivalents, and short-term investments totaled $216.0 million at year-end. The company has made substantial progress in each of their five portfolio programs.

Altimmune reported financial results for the third quarter ended September 30, 2020, with a revenue of $2.9 million and a net loss of $17.8 million, or $0.54 net loss per share. The company had cash, cash equivalents, and short-term investments of $206.8 million at the end of the quarter.

Altimmune reported a net loss of $16.8 million for the second quarter of 2020, compared to a net loss of $3.4 million for the same period in 2019. The company's revenue was $0.7 million, a decrease from $1.6 million in the prior year period. However, they had $80.3 million in cash, cash equivalents and short-term investments at the end of the quarter, and subsequently received approximately $136.2 million in net proceeds.

Altimmune reported a net loss attributed to common stockholders of $3.9 million, or ($0.26) per share, for the quarter ended March 31, 2020. Revenue was $2.2 million compared to $3 million in the prior year period. The company's cash, cash equivalents and short-term investments were $33 million at March 31, 2020.

Altimmune announces financial results for the year ended December 31, 2019. The company had cash, cash equivalents and short-term investments of $37.3 million. Revenue was $5.8 million and net loss was $20.97 million, or ($1.60) per share.